Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Diseases›Condition·Updated Jun 26, 2026·v1

Cellulitis

Cellulitis is a common acute bacterial skin infection caused primarily by streptococci and S. aureus. Diagnosis is clinical, with severity assessed by the Dundee classification. Management involves beta-lactam antibiotics for 5–7 days, with early IV-to-oral switch. Key complications include necrotizing fasciitis and recurrence, which can be prevented with penicillin prophylaxis and compression therapy.

High Evidence196 references·7,904 words·32 min read·v1
cellulitisskin infectionABSSSIerysipelasnecrotizing fasciitisMRSAstreptococcusstaphylococcusantibioticsinfectious disease

Quick Reference

RxDrug of choiceFor nonpurulent cellulitis: [[cephalexin]] 500 mg PO QID or [[amoxicillin]] 500 mg PO TID for 5–7 days.
AltAlternativesFor penicillin allergy: [[clindamycin]] 300–450 mg PO TID or [[doxycycline]] 100 mg PO BID. For IV therapy: [[cefazolin]] 2 g IV q8h or [[ceftriaxone]] 1–2 g IV daily. For MRSA coverage: [[vancomycin]], [[linezolid]], [[daptomycin]], or [[oritavancin]].
⊘Avoid[[Trimethoprim-sulfamethoxazole]] monotherapy for suspected streptococcal cellulitis; non-dihydropyridine CCBs (not relevant here).
DxTest of choiceClinical diagnosis; blood cultures only if systemic toxicity; [[LRINEC score]] for necrotizing fasciitis suspicion.
ScKey score[[Dundee classification]] for severity stratification; [[LRINEC score]] for necrotizing fasciitis.
→When to referSuspected [[necrotizing fasciitis]] (urgent surgical consult); failure to improve after 48–72h; recurrent cellulitis for prophylaxis.
Cellulitis is a clinical diagnosis; beta-lactam monotherapy is first-line for nonpurulent cases; early oral switch and short duration (5–7 days) are safe; address [[lymphedema]] and obesity to prevent recurrence.
Cellulitis is an acute bacterial infection of the deep dermis and subcutaneous tissue, most commonly caused by β-hemolytic streptococci and *Staphylococcus aureus*. Diagnosis is clinical, based on spreading erythema with indistinct borders, warmth, tenderness, and edema. Management depends on severity: mild cases are treated with oral beta-lactams for 5–7 days, while moderate-to-severe cases require intravenous antibiotics with early switch to oral therapy. The key to management is excluding [[necrotizing fasciitis]] and addressing risk factors for recurrence, such as [[lymphedema]] and obesity.

Overview and Recommendations

Background

  • •Cellulitis is an acute bacterial infection of the deep dermis and subcutaneous tissue, characterized by spreading erythema, warmth, edema, and tenderness — it is the most common acute bacterial skin and skin structure infection (ABSSSI), accounting for 14.5 million ambulatory visits and 650,000 hospitalizations annually in the United States, with costs exceeding $3.74 billion.
  • •The predominant pathogens are β-hemolytic streptococci (groups A, C, G) and Staphylococcus aureus; community-acquired MRSA (USA300 clone) is a common cause of purulent cellulitis and abscesses, while immunocompromised hosts may harbor unusual organisms such as Cryptococcus neoformans, Helicobacter cinaedi, or mycobacteria.
  • •Pathogenesis begins with a breach in the epidermal barrier (often trivial), followed by bacterial adherence via surface adhesins, immune evasion through M protein and capsular polysaccharide, and rapid tissue spread driven by hyaluronidase and streptokinase — the resulting inflammatory response produces the cardinal signs of erythema, warmth, edema, and pain.
  • •Chronic leg edema ( or ) is the strongest modifiable risk factor, increasing recurrence risk by 1.6-fold; obesity (BMI ≥30) confers a 2.4-fold increased risk, and injection drug use carries a pooled cellulitis prevalence of 8.2%.
  • •Recurrence occurs in 20–30% of patients within 3 years, driven by progressive lymphatic damage from each episode — this creates a vicious cycle that can be interrupted by prophylactic or compression therapy.

Evaluation

  • •Suspect cellulitis in any patient with acute onset of localized erythema, warmth, edema, and tenderness that progresses over hours to days, most commonly on the lower extremities.
  • •Ask about the inciting event: trauma, insect bite, ulcer, , or injection drug use; also inquire about systemic symptoms (fever, chills, malaise) and prior episodes of cellulitis.
  • •Examine the affected area for poorly defined, spreading margins (distinguishing it from which has a raised, well-demarcated border); note the presence of bullae, petechiae, or hemorrhage.
  • •Always examine the interdigital spaces for maceration, fissures, or tinea pedis — these are common portals of entry, especially for gram-negative toe web infections.
  • •Palpate for fluctuance (suggests abscess) and crepitus (suggests gas-forming infection); assess for lymphangitic streaking and regional lymphadenopathy.
  • •Evaluate for red flags that suggest : pain out of proportion to examination, rapid progression of erythema, skin necrosis, bullae, crepitus, or systemic toxicity (hypotension, altered mental status) — obtain urgent surgical consultation if present.
  • •Assess severity using the : mild (no systemic signs, no uncontrolled comorbidities), moderate (fever, tachycardia, or comorbidities), severe (marked systemic toxicity, rapid progression, or immunocompromise).
  • •Order blood cultures only if the patient has systemic toxicity (temperature >38.5°C, hypotension), immunocompromise, extremes of age, or failure to respond to initial therapy — yield is only 5–10%.
  • •Calculate the (Laboratory Risk Indicator for Necrotizing Fasciitis) if necrotizing infection is suspected: a score ≥6 has ~90% sensitivity and ~80% specificity for necrotizing fasciitis.
  • •Consider imaging: ultrasound to differentiate cellulitis from abscess or deep vein thrombosis; CT or MRI if necrotizing fasciitis is in the differential.
  • •Consider alternative diagnoses if presentation is atypical: stasis dermatitis (bilateral, chronic, no fever), contact dermatitis (pruritus, well-demarcated), deep vein thrombosis (unilateral swelling without fever), gout (acute monoarticular arthritis), or pyogenic flexor tenosynovitis (Kanavel signs).
  • •Reassess at 48–72 hours: clinical response (reduction in erythema, pain, and fever) confirms the diagnosis and guides therapy duration; failure to improve should prompt a search for abscess, resistant organisms, or an alternative diagnosis.

Management

  • •For mild cellulitis (Dundee class I), initiate oral beta-lactam therapy: 500 mg four times daily or 500 mg three times daily for 5–7 days.
  • •For penicillin-allergic patients with mild cellulitis, use 300–450 mg three times daily or 100 mg twice daily as alternatives.
  • •For moderate cellulitis (Dundee class II), start intravenous therapy: 2 g every 8 hours or 1–2 g daily; consider outpatient parenteral antimicrobial therapy (OPAT) for suitable patients.
  • •Switch from IV to oral therapy when the patient is afebrile for ≥24 hours, the cellulitis margin is no longer advancing, pain is improving, and oral intake is tolerated — typically within 24–48 hours.
  • •For severe cellulitis (Dundee class III–IV), admit to hospital and initiate empiric broad-spectrum therapy covering both streptococci and MRSA: 15–20 mg/kg IV every 8–12 hours (target trough 15–20 μg/mL) plus 4.5 g IV every 6 hours or 2 g IV every 8 hours.
  • •Alternative MRSA-active agents for severe disease include 600 mg IV/oral every 12 hours, 6 mg/kg IV daily, or 1200 mg IV as a single dose for patients requiring prolonged coverage who can be discharged early.
  • •Total duration of therapy is 5–7 days for most uncomplicated cellulitis; longer courses (10–14 days) are reserved for slow responders, immunocompromised patients, or those with significant comorbidities.
  • •If no clinical improvement after 48–72 hours of appropriate therapy, reassess with imaging (ultrasound, CT) to exclude abscess or necrotizing fasciitis, obtain blood cultures if not already done, and consider broadening coverage (e.g., adding MRSA coverage if not present).
  • •For any purulent collection, perform incision and drainage — alone are insufficient for abscesses.
  • •Provide supportive care: elevate the affected limb to reduce edema, use analgesics (acetaminophen 650–1000 mg every 6 hours or ibuprofen 400–600 mg every 6–8 hours) for pain and fever.
  • •Avoid routine addition of MRSA coverage for nonpurulent cellulitis without risk factors (prior MRSA, purulence, injection drug use, severe disease) — beta-lactam monotherapy is first-line.
  • •Do not use monotherapy for suspected streptococcal cellulitis due to inferior anti-streptococcal activity.
  • •Do not prolong IV therapy beyond 48–72 hours if clinical improvement occurs; early oral switch reduces length of stay and costs without compromising outcomes.
  • •For patients with two or more episodes of leg cellulitis, prescribe prophylactic V 250 mg twice daily for 12 months to reduce recurrence (HR 0.55, NNT = 8).
  • •Address predisposing factors: treat interdigital , manage chronic edema with compression therapy (graduated compression stockings 20–30 mmHg), and optimize glycemic control in diabetes.

Board Review — High Yield

  • •Nonpurulent cellulitis — most commonly caused by β-hemolytic streptococci; beta-lactam monotherapy is first-line.
  • •LRINEC score ≥6 — raises suspicion for [[necrotizing fasciitis]]; requires urgent surgical consultation.
  • •Dundee classification — stratifies severity (mild, moderate, severe) and predicts mortality (0.3% vs 6.7%).
  • •Early IV-to-oral switch — safe after 24–48 hours of clinical improvement; reduces length of stay.
  • •Penicillin prophylaxis — 250 mg BID for 12 months reduces recurrence by 45% (NNT=8).
  • •Compression therapy — halves recurrence risk in patients with chronic leg edema.
  • •Do not routinely add MRSA coverage for nonpurulent cellulitis without risk factors.
  • •Do not use TMP-SMX monotherapy for suspected streptococcal cellulitis.
  • •Blood cultures — low yield (5–10%); obtain only if systemic toxicity or immunocompromise.
  • •Obesity and heart failure — independent predictors of treatment failure.

Deep Dive — Evidence Details

References

  1. [1]

    Abrahamian FM, Sakoulas G, Tzanis E et al.. “Omadacycline for Acute Bacterial Skin and Skin Structure Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367742 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  2. [2]

    Bruun T, Oppegaard O, Hufthammer KO et al.. “Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27402819 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  3. [3]

    Sebeny PJ, Riddle MS, Petersen K. “Acinetobacter baumannii skin and soft-tissue infection associated with war trauma.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18611157 ↗

    L3CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications
  4. [4]

    Pahlitzsch R, Hammarin AL, Widell A. “A case of facial cellulitis and necrotizing lymphadenitis due to cowpox virus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 16912948 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management
  5. [5]

    Cardona AF, Wilson SE. “Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26316560 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  6. [6]

    Anaya DA, Dellinger EP. “Necrotizing soft-tissue infection: diagnosis and management.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17278065 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management
  7. [7]

    O'Toole RV, O'Hara NN, Carlini AR et al.. “Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.” JAMA (2026). PMID: 41984450 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  8. [8]

    Friedland HD, O'Neal T, Biek D et al.. “CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.” Antimicrobial agents and chemotherapy (2012). PMID: 22314524 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  9. [9]

    Prokocimer P, Bien P, Surber J et al.. “Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.” Antimicrobial agents and chemotherapy (2010). PMID: 21115795 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  10. [10]

    Rogers JH, Westley B, Mego T et al.. “Fatal Borealpox in an Immunosuppressed Patient Treated With Antivirals and Vaccinia Immunoglobulin-Alaska, 2023.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39499668 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  11. [11]

    Gloviczki P, Gloviczki ML, Mohos B et al.. “Microsurgical treatment of lower extremity lymphedema: A PEER umbrella systematic review supporting the American Venous Forum and the American Vein and Lymphatic Society clinical practice guidelines on management of lymphedema.” Journal of vascular surgery. Venous and lymphatic disorders (2026). PMID: 42208734 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management
  12. [12]

    Friedman ER, Juliano AF, Hagiwara M et al.. “ACR Appropriateness Criteria® Vision Loss.” Journal of the American College of Radiology : JACR (2025). PMID: 41193055 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms
  13. [13]

    Hafkin B, Kaplan N, Murphy B. “Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities.” Antimicrobial agents and chemotherapy (2015). PMID: 26711777 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  14. [14]

    Franco-Paredes C, Marcos LA, Henao-Martínez AF et al.. “Cutaneous Mycobacterial Infections.” Clinical microbiology reviews (2018). PMID: 30429139 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management
  15. [15]

    Cranendonk DR, Hugenholtz F, Prins JM et al.. “The Skin Microbiota in Patients Hospitalized for Cellulitis and Association With Outcome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30321312 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Prognosis and Natural History
  16. [16]

    Siljander T, Karppelin M, Vähäkuopus S et al.. “Acute bacterial, nonnecrotizing cellulitis in Finland: microbiological findings.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18260753 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  17. [17]

    Jenkins TC, Sabel AL, Sarcone EE et al.. “Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20839951 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  18. [18]

    Zeyen C, Abeck D, Becker K et al.. “S1 Guideline on Infected Interdigital Intertrigo (also called Gram-Negative Toe Web Infection).” Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2026). PMID: 41919364 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management
  19. [19]

    Coburn B, Morris AM, Tomlinson G et al.. “Does this adult patient with suspected bacteremia require blood cultures?” JAMA (2012). PMID: 22851117 ↗

    L2CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Complications, Prevention, Infection Control and Special Populations
  20. [20]

    Ciccarese G, Sbarra G, Liguori G et al.. “Bullous Wells' Syndrome: Case Report and Systematic Review.” Journal of clinical medicine (2025). PMID: 41375673 ↗

    L4SR_OBSCited in: Definition, Classification and Causative Organisms, Definitive Therapy, Duration and De-escalation
  21. [21]

    Bruun T, Oppegaard O, Kittang BR et al.. “Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.” Open forum infectious diseases (2015). PMID: 26734653 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management
  22. [22]

    Raff AB, Kroshinsky D. “Cellulitis: A Review.” JAMA (2016). PMID: 27434444 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  23. [23]

    Alkholaiwi F, Zamil Alzamil L, Mohammed Alotaibi R et al.. “Navigating the orbital complications of endoscopic sinus surgery: a systematic review of 204,286 patients.” Frontiers in surgery (2026). PMID: 41815776 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  24. [24]

    Moellering RC. “A 39-year-old man with a skin infection.” JAMA (2007). PMID: 18056894 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  25. [25]

    Zanetti E, Quaglia D, De Francesco F et al.. “An Overview of Red Breast Syndrome: A Qualitative Systematic Review of the Literature and a Single-center Case Series.” Aesthetic surgery journal (2026). PMID: 41784074 ↗

    L4SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation
  26. [26]

    Gordon CB, Ollech A, Test G et al.. “Cell-free DNA Levels in Cellulitis: A Cross-sectional Prospective Study.” Acta dermato-venereologica (2026). PMID: 42231633 ↗

    L4COHORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  27. [27]

    Bansal AA, Sachdeva V, Kekunnaya R. “Infection post strabismus surgery: A review and case series.” Survey of ophthalmology (2026). PMID: 41747837 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  28. [28]

    Newman N, Bantikassegn A, West TG et al.. “An Unusual Etiology of Lemierre-Like Syndrome: Preseptal Cellulitis due to Methicillin-Resistant Staphylococcus aureus.” Open forum infectious diseases (2022). PMID: 35531375 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Complications
  29. [29]

    Hamad HM, Specht CA, Carlson D et al.. “Primary Cryptococcal Cellulitis With High Antigenemia in an Immunocompromised Host: A Case Report and Laboratory Investigation of the Causative Cryptococcus neoformans Strain.” Open forum infectious diseases (2026). PMID: 42311648 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Prevention, Infection Control and Special Populations
  30. [30]

    Mascitti H, Sivadon-Tardy V, Bougnoux ME et al.. “Arthritis Caused by Nannizziopsis obscura, France.” Emerging infectious diseases (2022). PMID: 35997528 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  31. [31]

    Vivoda T, Rojko T, Ulčar BK et al.. “Mycoplasma arginini Cellulitis, Tenosynovitis, and Arthritis in Kidney Transplant Recipient, Slovenia, 2024.” Emerging infectious diseases (2025). PMID: 40439509 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prevention, Infection Control and Special Populations
  32. [32]

    Abu-Zeinah K, Lueck BD, Fuentes SA et al.. “Sphingobacterium hotanense Infections in Immunocompromised Patients, United States.” Emerging infectious diseases (2026). PMID: 41612589 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  33. [33]

    Bonwitt J, Tran M, Droz A et al.. “Psychrobacter sanguinis Wound Infection Associated with Marine Environment Exposure, Washington, USA.” Emerging infectious diseases (2018). PMID: 30226173 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  34. [34]

    Guo Y, Ramos RI, Cho JS et al.. “In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.” Antimicrobial agents and chemotherapy (2012). PMID: 23208713 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  35. [35]

    Goldstein EJC, Citron DM, Tyrrell KL et al.. “Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates.” Antimicrobial agents and chemotherapy (2018). PMID: 29439969 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  36. [36]

    Ruhe JJ, Menon A. “Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2007). PMID: 17576834 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  37. [37]

    Bouchiat C, Curtis S, Spiliopoulou I et al.. “MRSA infections among patients in the emergency department: a European multicentre study.” The Journal of antimicrobial chemotherapy (2016). PMID: 27798212 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  38. [38]

    Bettuzzi T, Strady C, Diamantis S et al.. “Differences in prescription for impetigo and cellulitis across years in three European countries.” The Journal of antimicrobial chemotherapy (2026). PMID: 41182839 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  39. [39]

    Lee R, Arnold DE, Parta M et al.. “Pre- and peri-hematopoietic cell transplant management of disseminated non-Helicobacter pylori Helicobacter infection in X-linked agammaglobulinemia: Case series and literature review.” Clinical immunology (Orlando, Fla.) (2026). PMID: 41713716 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms
  40. [40]

    Taggart M, Langworthy K, Hui S et al.. “Serological Responses to Streptococcus pyogenes Vaccine Candidate Antigens Suggests That Streptococcus dysgalactiae Is the Predominant Cause of Lower Limb Cellulitis.” Open forum infectious diseases (2024). PMID: 38872850 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  41. [41]

    Sutton JD, Carico R, Burk M et al.. “Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation.” Open forum infectious diseases (2020). PMID: 32010738 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  42. [42]

    Housman E, Livings SE, Knee A et al.. “Improving Management of Hospitalized Adults With Uncomplicated Cellulitis or Cutaneous Abscess.” Open forum infectious diseases (2017). PMID: 29497628 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Complications
  43. [43]

    Sirijatuphat R, Nookeu P, Thamlikitkul V. “Effectiveness of Implementing a Locally Developed Antibiotic Use Guideline for Community-Acquired Cellulitis at a Large Tertiary Care University Hospital in Thailand.” Open forum infectious diseases (2020). PMID: 33134410 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Complications
  44. [44]

    Wajima T, Morozumi M, Hanada S et al.. “Molecular Characterization of Invasive Streptococcus dysgalactiae subsp. equisimilis, Japan.” Emerging infectious diseases (2016). PMID: 26760778 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  45. [45]

    Nevanlinna V, Aittoniemi J, Huttunen R et al.. “Clinical Aspects and Disease Severity of Streptococcus dysgalactiae Subspecies equisimilis Bacteremia, Finland1.” Emerging infectious diseases (2024). PMID: 39173664 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric and Acute Management, Prognosis and Natural History
  46. [46]

    Roupie AL, Lafont E, Fraitag S et al.. “Recurrent Cellulitis Revealing Helicobacter cinaedi in Patient on Ibrutinib Therapy, France.” Emerging infectious diseases (2023). PMID: 36823687 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup
  47. [47]

    Hayward A, Knott F, Petersen I et al.. “Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England.” Emerging infectious diseases (2008). PMID: 18439352 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  48. [48]

    Watts V, Balasegaram S, Brown CS et al.. “Increased Risk for Invasive Group A Streptococcus Disease for Household Contacts of Scarlet Fever Cases, England, 2011-2016.” Emerging infectious diseases (2019). PMID: 30602121 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric and Acute Management
  49. [49]

    Marrie TJ, Tyrrell GJ, Majumdar SR et al.. “Concurrent Infection with Hepatitis C Virus and Streptococcus pneumoniae.” Emerging infectious diseases (2017). PMID: 28628455 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  50. [50]

    Crisp JG, Takhar SS, Moran GJ et al.. “Inability of polymerase chain reaction, pyrosequencing, and culture of infected and uninfected site skin biopsy specimens to identify the cause of cellulitis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26240200 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  51. [51]

    Taira KG, Wang M, Guo W et al.. “Association of Cellulitis With Obesity: Systematic Review and Meta-Analysis.” JMIR dermatology (2024). PMID: 39163102 ↗

    L1SR_OBSCited in: Microbiology and Pathogenesis
  52. [52]

    Palmer A, Carter M, Yeo J et al.. “Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study.” The Medical journal of Australia (2026). PMID: 42289398 ↗

    L2COHORTCited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History
  53. [53]

    Noble RK, Duplechin MO, Anwar AI et al.. “Erythromelalgia: Pathophysiology and Clinical Treatment Options, a Narrative Review.” Current pain and headache reports (2026). PMID: 42207226 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management
  54. [54]

    Valtellini L, Perego G, Aromolo IF et al.. “Dissecting Cellulitis of the Scalp: Current Insights and Therapeutic Advances.” American journal of clinical dermatology (2026). PMID: 41945009 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  55. [55]

    Mokos M, Šitum M, Masnec IS. “Dissecting Cellulitis of the Scalp: Linking Pathogenesis to Therapy.” Biomedicines (2026). PMID: 41898217 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  56. [56]

    Moore AY, Hurley KK. “Acne Conglobata: Understanding This Rare Form of Acne and Management Strategies.” Dermatology and therapy (2025). PMID: 40847255 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  57. [57]

    De-Pablo-Gómez-de-Liaño L, Ly-Yang F, Burgos-Blasco B et al.. “Ophthalmological Complications of Aesthetic Medicine Procedures: A Narrative Review.” Journal of clinical medicine (2025). PMID: 40807018 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  58. [58]

    Danielson DT, Lagerstrom I, Wary Z et al.. “Dermatologic Lesions with Eosinophilia in the Head and Neck.” Head and neck pathology (2025). PMID: 39998691 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  59. [59]

    Zhang Q, Song L, Fu M et al.. “Optogenetics in oral and craniofacial research.” Journal of Zhejiang University. Science. B (2024). PMID: 39155779 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  60. [60]

    Yosipovitch G, Nedorost ST, Silverberg JI et al.. “Stasis Dermatitis: An Overview of Its Clinical Presentation, Pathogenesis, and Management.” American journal of clinical dermatology (2023). PMID: 36800152 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  61. [61]

    Stefan M, Brajerova M, Prasad S et al.. “Recurrence following invasive GAS infections in adults: Triumph of virulence or failure of immunity?” Virulence (2025). PMID: 41017571 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis
  62. [62]

    Ridgway JP, Robicsek A, Shah N et al.. “A Randomized Controlled Trial of an Electronic Clinical Decision Support Tool for Inpatient Antimicrobial Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32712674 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  63. [63]

    Bruun T, Rath E, Madsen MB et al.. “Risk Factors and Predictors of Mortality in Streptococcal Necrotizing Soft-tissue Infections: A Multicenter Prospective Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 31923305 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  64. [64]

    Webb E, Neeman T, Bowden FJ et al.. “Compression Therapy to Prevent Recurrent Cellulitis of the Leg.” The New England journal of medicine (2020). PMID: 32786188 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Complications, Prognosis and Natural History
  65. [65]

    Fabre V, Sharara SL, Salinas AB et al.. “Does This Patient Need Blood Cultures? A Scoping Review of Indications for Blood Cultures in Adult Nonneutropenic Inpatients.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31942949 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications
  66. [66]

    Corey GR, Loutit J, Moeck G et al.. “Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.” Antimicrobial agents and chemotherapy (2018). PMID: 29358292 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  67. [67]

    Christensen KL, Holman RC, Steiner CA et al.. “Infectious disease hospitalizations in the United States.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19708796 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  68. [68]

    Peterson RA, Polgreen LA, Sewell DK et al.. “Warmer Weather as a Risk Factor for Cellulitis: A Population-based Investigation.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 30059959 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  69. [69]

    Carapetis JR, Jacoby P, Carville K et al.. “Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24785239 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy, Duration and De-escalation, Prevention, Infection Control and Special Populations
  70. [70]

    Wheeler A, Masters J, Pradhan A et al.. “Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.” Open forum infectious diseases (2025). PMID: 40160341 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  71. [71]

    Shah P, Pillari B, Margiotta N et al.. “Efficacy of vascularized lymph node transfer for lower extremity lymphedema: A systematic review and meta-analysis of 395 patients from 25 peer-reviewed studies.” Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2026). PMID: 41950607 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Complications
  72. [72]

    Ramadan MR, Angelin P, Atmodiwirjo P. “Recipient site selection in vascularized lymph node transfer for secondary lymphedema: A systematic review and meta-analysis.” Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2026). PMID: 41619498 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  73. [73]

    Zurfluh C, Ullmann H, Tung WS et al.. “Beyond volume reduction: Systematic review and meta-analysis of microsurgical treatment of lymphedema.” Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2025). PMID: 41202679 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  74. [74]

    Lingenheil I, Radacher L, Machens HG et al.. “One Surgery, Two Solutions: A Systematic Review of Combined Autologous Breast Reconstruction and Lymphatic Surgery.” Current oncology (Toronto, Ont.) (2026). PMID: 42346238 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  75. [75]

    Ren B, Wang Z, Rawaf S et al.. “Association between obesity and the risk of skin and soft tissue infections in European populations: A systematic review.” IJID regions (2026). PMID: 42232142 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  76. [76]

    Oliveira JA, Lemos MJ, Dias YJM et al.. “Postoperative oral cephalexin and metronidazole effectiveness in preventing complications in obese pregnant women undergoing cesarean delivery: A systematic review and meta-analysis.” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 41785716 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications, Prevention, Infection Control and Special Populations
  77. [77]

    Raimond E, Mimoun C, Menouer I et al.. “Systematic literature review and meta-analysis of postoperative complications of surgical management of vulvar cancer: what is the impact of frailty factors?” European journal of obstetrics, gynecology, and reproductive biology (2026). PMID: 41619338 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications
  78. [78]

    Hoefler F, Pouget-Abadie X, Roncato-Saberan M et al.. “Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001-2019.” Emerging infectious diseases (2022). PMID: 36418019 ↗

    L4REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  79. [79]

    Hudson FP, Homer N, Epstein A et al.. “Acute Chagas Disease Manifesting as Orbital Cellulitis, Texas, USA.” Emerging infectious diseases (2021). PMID: 34670654 ↗

    L4CASE_REPORTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  80. [80]

    Conway EL, Sellick JA, Kurtzhalts K et al.. “Obesity and Heart Failure as Predictors of Failure in Outpatient Skin and Soft Tissue Infections.” Antimicrobial agents and chemotherapy (2017). PMID: 28069657 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  81. [81]

    Cutfield T, Walter H, Hobbs M et al.. “Association of the Dundee severity classification with mortality, length of stay and readmission in adult inpatients with cellulitis.” The Journal of antimicrobial chemotherapy (2019). PMID: 30295790 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric and Acute Management, Prognosis and Natural History
  82. [82]

    Tyrrell GJ, Fathima S, Kakulphimp J et al.. “Increasing Rates of Invasive Group A Streptococcal Disease in Alberta, Canada; 2003-2017.” Open forum infectious diseases (2018). PMID: 30109241 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation
  83. [83]

    Peterson RA, Polgreen LA, Cavanaugh JE et al.. “Increasing Incidence, Cost, and Seasonality in Patients Hospitalized for Cellulitis.” Open forum infectious diseases (2017). PMID: 28480281 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  84. [84]

    Tseng HF, Sy LS, Qian L et al.. “Pneumococcal Conjugate Vaccine Safety in Elderly Adults.” Open forum infectious diseases (2018). PMID: 29977960 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric and Acute Management, Complications, Prevention, Infection Control and Special Populations
  85. [85]

    Zhang A, Surette MD, Schwartz KL et al.. “The Collapse of Infectious Disease Diagnoses Commonly Due to Communicable Respiratory Pathogens During the Coronavirus Disease 2019 Pandemic: A Time Series and Hierarchical Clustering Analysis.” Open forum infectious diseases (2022). PMID: 35791356 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  86. [86]

    Phillip KI, Webster AS, Ray SM et al.. “Estimating the Burden of Clinically Significant Staphylococcus aureus Infections and Predictors for Hospitalization for Skin and Soft Tissue Infections, Fulton County, Georgia, 2017.” Open forum infectious diseases (2023). PMID: 38107016 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  87. [87]

    Bocking N, Matsumoto CL, Loewen K et al.. “High Incidence of Invasive Group A Streptococcal Infections in Remote Indigenous Communities in Northwestern Ontario, Canada.” Open forum infectious diseases (2016). PMID: 28480241 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  88. [88]

    Bruce MG, Zulz T, DeByle C et al.. “Haemophilus influenzae serotype a invasive disease, Alaska, USA, 1983-2011.” Emerging infectious diseases (2013). PMID: 23735653 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prevention, Infection Control and Special Populations
  89. [89]

    Tan DH, Bunce PE, Liles WC et al.. “Gemcitabine-related "pseudocellulitis": report of 2 cases and review of the literature.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17682983 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  90. [90]

    Lamb SE, Marsh JL, Hutton JL et al.. “Mechanical supports for acute, severe ankle sprain: a pragmatic, multicentre, randomised controlled trial.” Lancet (London, England) (2009). PMID: 19217992 ↗

    L1RCTCited in: Clinical Presentation, Empiric and Acute Management, Prognosis and Natural History
  91. [91]

    Redor A, Danion F, Parize P et al.. “Devastating Gynecological Infections in Women with STAT3 Deficiency.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31916572 ↗

    L4OTHERCited in: Clinical Presentation, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  92. [92]

    Tyrrell GJ, Lovgren M, St Jean T et al.. “Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 21034198 ↗

    L2OTHERCited in: Clinical Presentation
  93. [93]

    Ruhe JJ, Smith N, Bradsher RW et al.. “Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17304447 ↗

    L3OTHERCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Empiric and Acute Management, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  94. [94]

    Fernandez-Figares-Conde L, Isorna I, Torres-Carranza E et al.. “Rhinocerebral mucormycosis: A 15-year retrospective study in southern Spain.” Medicina oral, patologia oral y cirugia bucal (2026). PMID: 41793736 ↗

    L4COHORTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  95. [95]

    Pal E, Štrumbelj I, Kišek TC et al.. “Haematospirillum jordaniae Cellulitis and Bacteremia.” Emerging infectious diseases (2022). PMID: 36148990 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  96. [96]

    Charret L, Bart G, Hoppe E et al.. “Clinical characteristics and management of olecranon and prepatellar septic bursitis in a multicentre study.” The Journal of antimicrobial chemotherapy (2021). PMID: 34293150 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  97. [97]

    Koerner R, Johnson AP. “Changes in the classification and management of skin and soft tissue infections.” The Journal of antimicrobial chemotherapy (2010). PMID: 21123287 ↗

    L5OTHERCited in: Clinical Presentation, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  98. [98]

    Goumboundi IA, Taylor S, Ayerkain NL et al.. “Snake envenomation and acute kidney injury: a systematic review and meta-analysis.” BMC nephrology (2026). PMID: 41776424 ↗

    L1SR_OBSCited in: Clinical Presentation
  99. [99]

    Almatroud L, Bayrak BY, Khachemoune A. “Primary Cutaneous Cryptococcosis in Immunocompetent Patients: Recognition and Management.” American journal of clinical dermatology (2026). PMID: 42240944 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Empiric and Acute Management, Prevention, Infection Control and Special Populations
  100. [100]

    Anderson GM, Proal JD, Crowe CS et al.. “Management of Pyogenic Flexor Tenosynovitis.” JBJS reviews (2026). PMID: 41996529 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup
  101. [101]

    McLuckey MN, Kemp JM, Meyers AB. “Imaging of acute musculoskeletal infections in children and their differential diagnoses.” Pediatric radiology (2026). PMID: 41838106 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  102. [102]

    Almarzoky Abuhussain SS, Burak MA, Adams DK et al.. “Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education.” Open forum infectious diseases (2018). PMID: 30310822 ↗

    L3OTHERCited in: Clinical Presentation, Empiric and Acute Management
  103. [103]

    Cheng D, Bensellam N, Sanchez K et al.. “Validation of International Classification of Diseases Codes for Dermatologic Conditions: A Systematic Review.” JAMA dermatology (2026). PMID: 41499108 ↗

    L1SR_OBSCited in: Diagnosis and Workup
  104. [104]

    Cross ELA, Hayward GN, Llewelyn MJ et al.. “External validation of the Baseline Recurrence Risk in Cellulitis (BRRISC) score and the added impact of acute clinical response: a prospective cohort study.” BMC infectious diseases (2025). PMID: 41466233 ↗

    L2COHORTCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  105. [105]

    Kaadan MI, Dennis M, Desai N et al.. “One Health Education for Future Physicians: A Case Report of Cat-Transmitted Sporotrichosis.” Open forum infectious diseases (2020). PMID: 32154323 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  106. [106]

    Pérez-Santiago J, Ramirez-Gaona M, Holm-Kennedy R et al.. “Bacteremia and Skin Infections in Four Patients Caused by Helicobacter-Like Organisms.” Open forum infectious diseases (2017). PMID: 31338379 ↗

    L4OTHERCited in: Diagnosis and Workup, Prevention, Infection Control and Special Populations
  107. [107]

    Taniguchi T, Tsuha S, Shiiki S et al.. “High Yield of Blood Cultures in the Etiologic Diagnosis of Cellulitis, Erysipelas, and Cutaneous Abscess in Elderly Patients.” Open forum infectious diseases (2022). PMID: 35899281 ↗

    L3OTHERCited in: Diagnosis and Workup, Empiric and Acute Management
  108. [108]

    Kamath RS, Sudhakar D, Gardner JG et al.. “Guidelines vs Actual Management of Skin and Soft Tissue Infections in the Emergency Department.” Open forum infectious diseases (2018). PMID: 29354655 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric and Acute Management
  109. [109]

    Liao CH, Liu LC, Huang YT et al.. “Bacteremia caused by group G Streptococci, taiwan.” Emerging infectious diseases (2008). PMID: 18439377 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  110. [110]

    Seiter D. “Case Report: Bimekizumab for dissecting cellulitis of the scalp.” Frontiers in immunology (2026). PMID: 42238601 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  111. [111]

    Nowak N, Farishta A, Chang R et al.. “Early Calciphylaxis Mimicking Infection in a Patient With End-Stage Renal Disease and Sarcoidosis: A Diagnostic and Wound Management Challenge.” International wound journal (2026). PMID: 42036346 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  112. [112]

    Tinggaard M, Johannesen TB, Hoffmann S et al.. “Periorbital infections caused by Group A streptococci: a case series.” BMC infectious diseases (2026). PMID: 41545920 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup, Definitive Therapy, Duration and De-escalation
  113. [113]

    Mehdizadeh M, Foster L, Cordero JJ et al.. “Antibiotics in Septorhinoplasty: Routine Necessity or Unnecessary Precaution? A Nationwide Propensity-Score Matched Retrospective Cohort Study.” Aesthetic plastic surgery (2026). PMID: 41559394 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations
  114. [114]

    Ren T, Galenchik-Chan A, Wang K et al.. “Comparison of Clinical Associations and Outcomes Between Superomedial and Inferior Pedicle Breast Reduction Surgery: A Retrospective Study.” Aesthetic plastic surgery (2025). PMID: 40634764 ↗

    L4COHORTCited in: Severity Assessment and Risk Stratification
  115. [115]

    Oliver-Gutierrez D, Ros-Sanchez E, Segura-Duch G et al.. “A Closer Look at Periocular Necrotizing Fasciitis: A Systematic Review of Literature.” Diagnostics (Basel, Switzerland) (2025). PMID: 40361999 ↗

    L1SR_OBSCited in: Severity Assessment and Risk Stratification, Prevention, Infection Control and Special Populations
  116. [116]

    Chung GC, Kim DS, Lee JE et al.. “Endogenous endophthalmitis due to Klebsiella pneumoniae liver abscess: a retrospective study of clinical course, treatment pattern, and prognosis.” International journal of ophthalmology (2025). PMID: 40827294 ↗

    L4COHORTCited in: Severity Assessment and Risk Stratification
  117. [117]

    Ehsani A, Falakian S, Ehsani A et al.. “Analysis of Hospitalization Cases for Filler Injection Complications: A Five-Year Retrospective Study Among Iranian People.” Journal of cosmetic dermatology (2024). PMID: 39681832 ↗

    L4COHORTCited in: Severity Assessment and Risk Stratification
  118. [118]

    Shah P, Hanson M, Waller JL et al.. “The Assessment of Infection Risk in Patients with Vitiligo Undergoing Dialysis for End-Stage Renal Disease: A Retrospective Cohort Study.” Pathogens (Basel, Switzerland) (2024). PMID: 38276167 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification
  119. [119]

    Xu B, Xu S, Tong Y et al.. “A missed case of a large occult intraorbital branch foreign body caused by tree branch laceration: case report.” Frontiers in medicine (2026). PMID: 42318422 ↗

    L4CASE_REPORTCited in: Severity Assessment and Risk Stratification, Empiric and Acute Management
  120. [120]

    Spellberg B, Talbot GH, Boucher HW et al.. “Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19555285 ↗

    L5SR_OBSCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  121. [121]

    O'Riordan W, Cardenas C, Shin E et al.. “Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2019). PMID: 31474458 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  122. [122]

    Moran GJ, Fang E, Corey GR et al.. “Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.” The Lancet. Infectious diseases (2014). PMID: 24909499 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  123. [123]

    Ibrahim LF, Hopper SM, Orsini F et al.. “Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2019). PMID: 30853250 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  124. [124]

    Ibrahim LF, Huang L, Hopper SM et al.. “Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis.” The Lancet. Infectious diseases (2019). PMID: 31420292 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  125. [125]

    Miller LG, Daum RS, Creech CB et al.. “Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.” The New England journal of medicine (2015). PMID: 25785967 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  126. [126]

    Thomas KS, Crook AM, Nunn AJ et al.. “Penicillin to prevent recurrent leg cellulitis.” The New England journal of medicine (2013). PMID: 23635049 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  127. [127]

    van Dongen TM, van der Heijden GJ, Venekamp RP et al.. “A trial of treatment for acute otorrhea in children with tympanostomy tubes.” The New England journal of medicine (2014). PMID: 24552319 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  128. [128]

    Daum RS, Miller LG, Immergluck L et al.. “A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.” The New England journal of medicine (2017). PMID: 28657870 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  129. [129]

    Kirsner RS, Marston WA, Snyder RJ et al.. “Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.” Lancet (London, England) (2012). PMID: 22863328 ↗

    L1RCTCited in: Empiric and Acute Management, Complications, Prognosis and Natural History
  130. [130]

    Stryjewski ME, Barriere SL, O'Riordan W et al.. “Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.” The Journal of antimicrobial chemotherapy (2012). PMID: 22416054 ↗

    L2SR_OBSCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  131. [131]

    Little P, Stuart B, Hobbs FD et al.. “Antibiotic prescription strategies for acute sore throat: a prospective observational cohort study.” The Lancet. Infectious diseases (2014). PMID: 24440616 ↗

    L2COHORTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  132. [132]

    Prokocimer P, De Anda C, Fang E et al.. “Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.” JAMA (2013). PMID: 23403680 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  133. [133]

    Moran GJ, Krishnadasan A, Mower WR et al.. “Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial.” JAMA (2017). PMID: 28535235 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications, Prognosis and Natural History
  134. [134]

    Dunbar LM, Milata J, McClure T et al.. “Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.” Antimicrobial agents and chemotherapy (2011). PMID: 21537018 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  135. [135]

    Aboltins CA, Hutchinson AF, Sinnappu RN et al.. “Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial.” The Journal of antimicrobial chemotherapy (2014). PMID: 25336165 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  136. [136]

    Clarke MC, Cheng AC, Pollard JG et al.. “Lessons Learned From a Randomized Controlled Trial of Short-Course Intravenous Antibiotic Therapy for Erysipelas and Cellulitis of the Lower Limb (Switch Trial).” Open forum infectious diseases (2019). PMID: 31660410 ↗

    L1RCTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Complications
  137. [137]

    Ritchie SR, Cutfield T, Lee A et al.. “The Impact of the Auckland Cellulitis Pathway on Length of Hospital Stay, Mortality Readmission Rate, and Antibiotic Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33639623 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  138. [138]

    Williams OM, Hamilton F, Brindle R. “The Natural History of Antibiotic-Treated Lower Limb Cellulitis: Analysis of Data Extracted From a Multicenter Clinical Trial.” Open forum infectious diseases (2023). PMID: 37849504 ↗

    L2TRIAL_NONRANDOMCited in: Empiric and Acute Management, Prognosis and Natural History
  139. [139]

    Alsohime F, Martin-Fernandez M, Temsah MH et al.. “JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency.” The New England journal of medicine (2020). PMID: 31940699 ↗

    L4CASE_REPORTCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  140. [140]

    Wong AW, Sim NH, Huang JJ. “Incorporating Lymphedema Reconstruction into Breast Reconstruction: Concepts, Approach, and Systematic Review.” Seminars in plastic surgery (2026). PMID: 42037628 ↗

    L2SR_OBSCited in: Empiric and Acute Management, Prognosis and Natural History
  141. [141]

    Díez-Madueño K, Argüello-Marcos B, Buendía-Castaño D et al.. “Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review.” Dermatology and therapy (2026). PMID: 41964799 ↗

    L2SR_OBSCited in: Empiric and Acute Management, Complications
  142. [142]

    Yetmar ZA, Chesdachai S, Lahr BD et al.. “Comparison of Oral and Intravenous Definitive Antibiotic Therapy for Beta-Hemolytic Streptococcus Species Bloodstream Infections from Soft Tissue Sources: a Propensity Score-Matched Analysis.” Antimicrobial agents and chemotherapy (2023). PMID: 37191533 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  143. [143]

    Taylor E, Nailor MD, Feider M et al.. “Doxycycline versus cephalexin treatment of presumed streptococcal skin and soft tissue infection among adults presenting to the emergency department.” Antimicrobial agents and chemotherapy (2024). PMID: 38169286 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  144. [144]

    Francis NA, Hood K, Lyons R et al.. “Understanding flucloxacillin prescribing trends and treatment non-response in UK primary care: a Clinical Practice Research Datalink (CPRD) study.” The Journal of antimicrobial chemotherapy (2016). PMID: 27090629 ↗

    L2OTHERCited in: Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  145. [145]

    Jones GR, Cumming DV, Honeywell G et al.. “How is income generated by outpatient parenteral antibiotic treatment (OPAT) in the UK? Analysis of payment tariffs for cellulitis.” The Journal of antimicrobial chemotherapy (2015). PMID: 25558074 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  146. [146]

    Kameshwar K, Karahalios A, Janus E et al.. “False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia.” The Journal of antimicrobial chemotherapy (2015). PMID: 26702920 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation
  147. [147]

    Bowen AC, Carapetis JR, Currie BJ et al.. “Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.” Open forum infectious diseases (2017). PMID: 29255730 ↗

    L2REVIEW_NARRATIVECited in: Empiric and Acute Management
  148. [148]

    Ihm C, Sutton JD, Timbrook TT et al.. “Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure.” Open forum infectious diseases (2019). PMID: 31211160 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  149. [149]

    Sawada O, Gotoh Y, Taniguchi T et al.. “Genome Sequencing Verifies Relapsed Infection of Helicobacter cinaedi.” Open forum infectious diseases (2019). PMID: 31139675 ↗

    L4OTHERCited in: Empiric and Acute Management, Antimicrobial Resistance and Stewardship
  150. [150]

    Dellsperger S, Kramer S, Stoller M et al.. “Early Switch From Intravenous to Oral Antibiotics in Skin and Soft Tissue Infections: An Algorithm-Based Prospective Multicenter Pilot Trial.” Open forum infectious diseases (2022). PMID: 35794940 ↗

    L2OTHERCited in: Empiric and Acute Management, Definitive Therapy, Duration and De-escalation, Prognosis and Natural History
  151. [151]

    Petrak RM, Skorodin NC, Fliegelman RM et al.. “Value and Clinical Impact of an Infectious Disease-Supervised Outpatient Parenteral Antibiotic Therapy Program.” Open forum infectious diseases (2016). PMID: 27807591 ↗

    L4OTHERCited in: Empiric and Acute Management
  152. [152]

    Redell M, Moeck G, Lucasti C et al.. “A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.” Open forum infectious diseases (2018). PMID: 29977954 ↗

    L4OTHERCited in: Empiric and Acute Management, Complications
  153. [153]

    Yang J, Wang T, Yang W et al.. “Case Report: A rare case of oesophageal cellulitis caused by Klebsiella pneumoniae: diagnosis, management, and literature review.” Frontiers in medicine (2026). PMID: 42078459 ↗

    L4CASE_REPORTCited in: Empiric and Acute Management, Prevention, Infection Control and Special Populations
  154. [154]

    Hennessy M, Forder BH, Tucker S et al.. “Optimal management of pyogenic flexor tenosynovitis of the hand: a cohort study.” Journal of hand and microsurgery (2026). PMID: 42239939 ↗

    L3COHORTCited in: Empiric and Acute Management
  155. [155]

    Micalo L, Archie M, Rowe VL et al.. “Glucagon-Like Peptide-1 Receptor Agonists are Associated with Fewer Venous Thromboembolic Events and Limb Complications in Obese Patients with Chronic Venous Insufficiency.” Journal of vascular surgery. Venous and lymphatic disorders (2026). PMID: 42323127 ↗

    L3OTHERCited in: Empiric and Acute Management
  156. [156]

    Craft JC, Moriarty SR, Clark K et al.. “A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21546629 ↗

    L1RCTCited in: Definitive Therapy, Duration and De-escalation
  157. [157]

    Mosites E, Frick A, Gounder P et al.. “Outbreak of Invasive Infections From Subtype emm26.3 Group A Streptococcus Among Homeless Adults-Anchorage, Alaska, 2016-2017.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29069346 ↗

    L4OTHERCited in: Definitive Therapy, Duration and De-escalation
  158. [158]

    Alfonso Arvez MJ, Tan GSQ, Ademi Z et al.. “Initiation of sodium-glucose cotransporter-2 inhibitors and the risk of infection-related hospitalisations: A population-based cohort study.” Diabetes, obesity & metabolism (2025). PMID: 41221689 ↗

    L3COHORTCited in: Definitive Therapy, Duration and De-escalation
  159. [159]

    Zhu J, Deng H, Li M et al.. “The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study.” Medicine (2026). PMID: 41686620 ↗

    L1RCTCited in: Definitive Therapy, Duration and De-escalation
  160. [160]

    McLaughlin D, Rait X, Janssens M et al.. “A case of orbital compartment syndrome caused by orbital abscess in an immunocompetent pediatric patient.” The American journal of emergency medicine (2026). PMID: 42314344 ↗

    L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation
  161. [161]

    Ramwani M, Solman L. “P13 The cellulitis that wasn't: a case of subcutaneous panniculitis-like T-cell lymphoma in a toddler.” The British journal of dermatology (2025). PMID: 41413007 ↗

    L4CASE_REPORTCited in: Definitive Therapy, Duration and De-escalation
  162. [162]

    Dagne A, Nibret G, Tefera ZH et al.. “Phytochemical screening and in vivo evaluation of antinociceptive and anti-inflammatory activities of aqueous, methanolic, and chloroform root fractions of Impatiens rothii Hook. (Balsaminaceae).” Inflammopharmacology (2026). PMID: 42082876 ↗

    L5OTHERCited in: Definitive Therapy, Duration and De-escalation
  163. [163]

    Wladis EJ, Aakalu VK, Dagi Glass LR et al.. “The Role of Corticosteroids in the Management of Orbital Cellulitis: A Report by the American Academy of Ophthalmology.” Ophthalmology (2026). PMID: 42053485 ↗

    L1REVIEW_NARRATIVECited in: Definitive Therapy, Duration and De-escalation
  164. [164]

    Thapa P, Shukla P, Joshi C et al.. “Impact of WHO AWaRe Antibiotic Handbook training on antibiotics prescribing knowledge among private primary care providers: a vignette-based, prep-post pilot study in Patna, India.” Antimicrobial resistance and infection control (2026). PMID: 41897013 ↗

    L4OTHERCited in: Definitive Therapy, Duration and De-escalation
  165. [165]

    Lipsky BA, Holroyd KJ, Zasloff M. “Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18990064 ↗

    L1RCTCited in: Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  166. [166]

    Cooper BJ, Mitchell ML, Melamed S et al.. “Improving Antibiotic Use in Pediatric Preseptal Cellulitis Using a Clinical Practice Guideline.” Hospital pediatrics (2024). PMID: 39246158 ↗

    L4GUIDELINECited in: Antimicrobial Resistance and Stewardship
  167. [167]

    Pacanowski J, Lalande V, Lacombe K et al.. “Campylobacter bacteremia: clinical features and factors associated with fatal outcome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18699745 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention, Infection Control and Special Populations
  168. [168]

    Mo Y, Tan WC, Cooper BS. “Antibiotic duration for common bacterial infections-a systematic review.” JAC-antimicrobial resistance (2025). PMID: 39881797 ↗

    L1SR_OBSCited in: Antimicrobial Resistance and Stewardship
  169. [169]

    Lin V, Callado GY, Pardo I et al.. “Diagnostic stewardship and dermatology consultation in cellulitis management: a systematic literature review and meta-analysis.” Archives of dermatological research (2024). PMID: 39614879 ↗

    L1SR_OBSCited in: Antimicrobial Resistance and Stewardship
  170. [170]

    Broussard KA, Chaparro JD, Erdem G et al.. “Default Antibiotic Order Durations for Skin and Soft Tissue Infections in Outpatient Pediatrics: A Cluster Randomized Trial.” Journal of the Pediatric Infectious Diseases Society (2025). PMID: 39665614 ↗

    L1RCTCited in: Antimicrobial Resistance and Stewardship
  171. [171]

    LaVergne S, Gaufin T, Richman D. “Myroides injenensis Bacteremia and Severe Cellulitis.” Open forum infectious diseases (2019). PMID: 31334299 ↗

    L4REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Prevention, Infection Control and Special Populations
  172. [172]

    Rodríguez Santos F, Bottini O, Nuccetelli Y et al.. “[Prevention and treatment of infections in phlebology and lymphology].” Medicina (2025). PMID: 40793892 ↗

    L5GUIDELINECited in: Antimicrobial Resistance and Stewardship
  173. [173]

    Mori T, Yoshizawa S, Yamada K et al.. “Pseudomonas otitidis bacteremia in an immunocompromised patient with cellulitis: case report and literature review.” BMC infectious diseases (2023). PMID: 38110897 ↗

    L4CASE_REPORTCited in: Antimicrobial Resistance and Stewardship
  174. [174]

    Glennon CM, El Saleeby C, Kroshinsky D. “Cellulitis in Pediatric Patients: Recognition and Management in the Era of Evolving Resistance.” American journal of clinical dermatology (2025). PMID: 40259138 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  175. [175]

    Orbay H, Ziembicki JA, Yassin M et al.. “Prevention and Management of Wound Infections in Burn Patients.” Clinics in plastic surgery (2023). PMID: 38429048 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  176. [176]

    Drobot RB, Lipa M, Antoniewicz AA. “Salvage Ultrasound-Guided Robot-Assisted Video-Endoscopic Inguinal Lymphadenectomy (RAVEIL) as a Metastasis-Directed Therapy (MDT) in Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case Report and Review of the Literature.” Current oncology (Toronto, Ont.) (2025). PMID: 39996915 ↗

    L5CASE_REPORTCited in: Antimicrobial Resistance and Stewardship
  177. [177]

    Rost LM, Nguyen MH, Clancy CJ et al.. “Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices.” Open forum infectious diseases (2020). PMID: 33447636 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  178. [178]

    Noel GJ, Bush K, Bagchi P et al.. “A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18225981 ↗

    L1RCTCited in: Complications
  179. [179]

    Cordonnier C, Ljungman P, Juergens C et al.. “Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25870329 ↗

    L2TRIAL_NONRANDOMCited in: Complications, Prevention, Infection Control and Special Populations
  180. [180]

    Lewer D, Brothers TD, Croxford S et al.. “Opioid Injection-Associated Bacterial Infections in England, 2002-2021: A Time Series Analysis of Seasonal Variation and the Impact of Coronavirus Disease 2019.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36916065 ↗

    L2OTHERCited in: Complications
  181. [181]

    Dechet AM, Yu PA, Koram N et al.. “Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18444811 ↗

    L2OTHERCited in: Complications, Prognosis and Natural History
  182. [182]

    Acker ES, Martin Gonzalez G, Davie D et al.. “Adjunctive systemic corticosteroids in pediatric orbital cellulitis: a systematic review and meta-analysis.” Frontiers in pediatrics (2026). PMID: 42088754 ↗

    L1SR_OBSCited in: Complications
  183. [183]

    Gao Y, Guyatt G, Zhao W et al.. “Global complications among patients with mpox: a systematic review and meta-analysis.” EClinicalMedicine (2026). PMID: 42078098 ↗

    L1SR_OBSCited in: Complications
  184. [184]

    Meroni M, Martini F, Scaglioni MF. “Systematic Review of Vascularized Lymphatic Vessel Transfer for the Treatment and Prevention of Lymphedema.” Journal of reconstructive microsurgery (2026). PMID: 41730302 ↗

    L2SR_OBSCited in: Complications
  185. [185]

    Curman P, Dräger S, Olbrich H et al.. “Identifying common risk factors for primary cellulitis in a large-scale retrospective cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41722760 ↗

    L2COHORTCited in: Complications
  186. [186]

    Pallin DJ, Binder WD, Allen MB et al.. “Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 23457080 ↗

    L1RCTCited in: Prognosis and Natural History
  187. [187]

    Brown S, Shen Y, Klimitz FJ et al.. “Lymphovenous bypass for the treatment of secondary lymphedema: A meta-analysis of prospective outcomes.” Breast cancer research and treatment (2025). PMID: 41396216 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  188. [188]

    Nicholas Jungbauer W, Solomon S, Verhey EM et al.. “Lymphovenous Anastomosis and Vascularized Lymph Node Transfer Reduce Long-term Cellulitis Events in Patients With Secondary Lymphedema: A Systematic Review and Meta-analysis.” Annals of plastic surgery (2025). PMID: 41071856 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  189. [189]

    Shimbo K, Aoki Y. “Surgical Treatment for Extremity Lymphedema Reduces Frequency of Cellulitis Episodes: A Cohort Study and Meta-Analysis.” Journal of reconstructive microsurgery (2026). PMID: 41730304 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  190. [190]

    Bookstaver PB, Jenkins TC, Stenehjem E et al.. “Impact of Outpatient vs Inpatient ABSSSI Treatment on Outcomes: A Retrospective Observational Analysis of Medical Charts Across US Emergency Departments.” Open forum infectious diseases (2018). PMID: 30581883 ↗

    L2OTHERCited in: Prognosis and Natural History
  191. [191]

    Schiffer JT, Levy C, Hughes SM et al.. “Stable HIV Reservoir Despite Prolonged Low-Dose Mycophenolate to Limit CD4+ T-cell Proliferation.” Open forum infectious diseases (2022). PMID: 36519118 ↗

    L2OTHERCited in: Prognosis and Natural History
  192. [192]

    Ahmed A, Cahn B, Haber R. “Wells syndrome: emerging triggers and treatments- an updated systematic review.” Archives of dermatological research (2025). PMID: 40488888 ↗

    L2SR_OBSCited in: Prevention, Infection Control and Special Populations
  193. [193]

    Heidari N, Ghannadzadeh Kermani Pour R, Farshbafnadi M et al.. “A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment.” Orphanet journal of rare diseases (2025). PMID: 40383754 ↗

    L1SR_OBSCited in: Prevention, Infection Control and Special Populations
  194. [194]

    Saba BV, Higuera-Rueda CA, Dundon J et al.. “The Three-Month Wound Complication and Infection Rates After Vancomycin Powder and Dilute Povidone-Iodine Lavage for Infection Prophylaxis in High-Risk Total Joint Arthroplasty: A Multicenter Randomized Controlled Trial.” The Journal of arthroplasty (2025). PMID: 40349869 ↗

    L1RCTCited in: Prevention, Infection Control and Special Populations
  195. [195]

    Sierla R, Fearn N, Nube V et al.. “Secondary prevention of cellulitis: A systematic review.” Phlebology (2025). PMID: 41275489 ↗

    L2SR_OBSCited in: Prevention, Infection Control and Special Populations
  196. [196]

    Kitaura S, Okamoto K, Wakabayashi Y et al.. “A Cold-Blooded Tiptoer: Nonresolving Cellulitis in an Immunocompromised Patient.” Open forum infectious diseases (2022). PMID: 35308485 ↗

    L4CASE_REPORTCited in: Prevention, Infection Control and Special Populations

Revision History

All updates applied to this page

Loading revisions…